Xingxin Wu
State Key Laboratory Of Pharmaceutical Biotechnology
Nanjing, 210093, China
Nanjing, 210093, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 29 publications
Macrophage FOLR2 drives liver fibrosis via intercellular engagement of TGFβRII.
Journal: Acta pharmacologica Sinica
Published: February 26, 2026
A small interfering RNA inhibits lung fibroblast-myofibroblast differentiation via simultaneously knockingdown CELF1 and activating RIG-I signalling.
Journal: Biochimica et biophysica acta. Molecular cell research
Published: September 30, 2024
T Cell-Specific Deficiency of Src Homology 2-Containing Protein Tyrosine Phosphatase 2 Ameliorates Psoriasis and Colitis by Promoting Treg Differentiation.
Journal: MedComm
Published: September 05, 2024
Identification of an RNA-binding perturbing characteristic for thiopurine drugs and their derivatives to disrupt CELF1-RNA interaction.
Journal: Nucleic acids research
Published: March 26, 2024
HSD17B13 liquid-liquid phase separation promotes leukocyte adhesion in chronic liver inflammation.
Journal: Journal of molecular cell biology
Published: November 01, 2023
Mitochondrial folate metabolism-mediated α-linolenic acid exhaustion masks liver fibrosis resolution.
Journal: The Journal of biological chemistry
Published: December 21, 2022
Neuron stem cell NLRP6 sustains hippocampal neurogenesis to resist stress-induced depression.
Journal: Acta pharmaceutica Sinica. B
Published: November 01, 2022
Rational design, synthesis and biological evaluation of dual PARP-1/2 and TNKS1/2 inhibitors for cancer therapy.
Journal: European journal of medicinal chemistry
Published: March 09, 2022
Targeted Isolation of a Cytotoxic Cyclic Hexadepsipeptide from the Mesophotic Zone Sponge-Associated Fungus Cymostachys sp. NBUF082.
Journal: Marine drugs
Published: September 12, 2021
Small molecule targeting CELF1 RNA-binding activity to control HSC activation and liver fibrosis.
Journal: Nucleic acids research
Published: September 08, 2021
CXCR6 is required for antitumor efficacy of intratumoral CD8+ T cell.
Journal: Journal for immunotherapy of cancer
Published: August 15, 2021
Last Updated: 09/26/2026